摘要
目的:探讨非干预性观察甲磺酸阿帕替尼对表皮生长因子受体(EGFR)野生或未明的晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法:选取2015年8月至2017年4月某院就诊化疗失败的34例EGFR野生或未明的晚期NSCLC患者,以口服甲磺酸阿帕替尼(425mg·d-1)为主要治疗,观察其无进展生存期(PFS)、客观缓解率(ORR)和疾病控制率(DCR),随访相关不良事件。结果:34例患者中可评价疗效者30例,中位PFS(m PFS)为3.75个月(95%CI:0.648~6.852),ORR为20%,其中部分缓解(PR)6例(20.00%),疾病稳定(SD)16例(53.33%),进展(PD)7例(23.33%),DCR为73.33%。不良反应主要有高血压18例(52.94%)、手足综合征18例(52.94%)、蛋白尿15例(44.12%)和乏力14例(41.18%),无药物相关性死亡。疗效相关性分析显示ECOG评分0~1分和联合化疗是延长PFS的因素,联合化疗为独立预后因子。结论:甲磺酸阿帕替尼治疗化疗失败的晚期NSCLC有良好疗效,不良反应可期可控,有进一步开展大规模临床研究的价值。
Objective:To investigate the efficacy and safety of apatinib with non-interfered in patients with EGFR gene wild type or unknown of advanced non-small cell lung cancer(NSCLC),and explore the possible related factors of the effect.Methods:All the patients come from our hospital which is chemotherapy-faild advanced NSCLC of EGFR genes wild type or unknown from August2015to April2017.All the patients received apatinib425mg once daily orally in4-weeks cycle and adverse events were followed up.The end point was progress free survival(PFS),objective response rate(ORR),disease control rate(DCR).Results:Thirty-four patients were enrolled,of which the efficacy can be evaluated in30patients while the other4can not because of severe adverse events.The total median PFS was3.75months(95%CI:0.648~6.852).The number of response were:partial remission(PR)6cases(20.00%),stead disease(SD)16cases(53.33%),progress disease(PD)7cases(23.33%).The overall response rate(ORR)and the disease control rate(DCR)were20%,73.33%respectively.The most frequently observed adverse event were18cases hypertension(52.94%),18cases hand-foot syndrome(52.94%),15cases proteinuria(44.12%),and14cases fatigue(41.18%).No medicine-related death were found.Correlation analysis showed ECOG0~1and combination chemotherapy were two affecting factors of PFS,and the latteris independent predictor.Conclusion:The treatment of chemotherapy-faild advanced non-small lung cancer with apatinib have better exact affect,and toxicity could be controlled.So it has certain value of clinical application or large-scale clinical research.
作者
范少泷
邹玉环
房芳
王毅峰
宋文广
FAN Shaoshuang;ZOU Yuhuan;FANG Fang;WANG Yifeng;SONG Wenguang(North China University of Science and Technology,Hebei Tangshan063000,China;Department of Oncology,Kailuan General Hospital,Hebei Tangshan063000,China;Department of Oncologya,Tangshan City Worker′s Hospital,Hebei Tangshan063000,China;Department of Gynecologyb,Tangshan City Worker′s Hospital,Hebei Tangshan063000,China)
出处
《中国医药导刊》
2017年第11期1150-1154,共5页
Chinese Journal of Medicinal Guide
基金
唐山市科技局科技攻关计划项目(项目编号:10130215a
项目名称:磁共振增强扫描在脑肿瘤非手术治疗中的应用研究)
